Mitchell Kapoor

H.C. Wainwright & Co.

Recent Articles about Sarepta Therapeutics Inc.

Biotech Co. Faces Mounting ELEVIDYS Efficacy Risk as Roche Phase 3 Study Threatens US Franchise 05/04/2026

H.C. Wainwright analysts argue that Roche's new placebo-controlled Phase 3 study of ELEVIDYS, while aimed at reopening the European market, creates significant downside risk for Sarepta Therapeutics Inc.'s (SRPT:NASDAQ) core U.S. ambulatory business by potentially generating another failed NSAA readout.

Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline 03/26/2026

H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics Inc. (SRPT:NASDAQ), arguing that promising but early-stage siRNA muscle concentration data in DM1 and FSHD cannot compensate for falling ELEVIDYS sales, a fatal adverse event in SRP-1003, and intensifying competition from Avidity and Dyne ahead of a potential 2030 market entry.